Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis - Takeaways - MDSpire

Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis

  • By

  • Bernhard Neumann

  • Julia Onken

  • Nicole König

  • Henning Stetefeld

  • Sebastian Luger

  • Anna-Luisa Luger

  • Felix Schlachetzki

  • Ralf Linker

  • Peter Hau

  • Elisabeth Bumes

  • August 2, 2023

  • 0 min

Share

  • 1

    Glioblastoma is the most common primary malignant brain tumor, with a median overall survival of 12 to 18 months despite aggressive treatment.

  • 2

    Patients with glioblastoma often require ICU admission due to complications like respiratory failure, septic shock, and refractory seizures.

  • 3

    A multicenter study identified 33 glioblastoma patients requiring invasive mechanical ventilation, with infections being the primary reason for ICU admission.

  • 4

    The study found that many glioblastoma patients discharged from ICU had stable or improved functional status, indicating potential recovery.

  • 5

    Regular reassessment of treatment goals is crucial for glioblastoma patients in the ICU due to their poor prognosis and complex care needs.

Original Source(s)

Outcome of glioblastoma patients after intensive care unit admission with invasive mechanical ventilation: a multicenter analysis

  • by Bernhard Neumann, Julia Onken, Nicole König, Henning Stetefeld, Sebastian Luger, Anna-Luisa Luger, Felix Schlachetzki, Ralf Linker, Peter Hau, Elisabeth Bumes

  • August 2, 2023

Related Content

Delayed Platelet Engraftment and Ongoing Pulmonary Infection Following Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation: A Case Study

Beta-lactam dose reductions in critically ill patients with acute kidney injury: a scoping review

Jacqueline Garcia, MD on oral maintenance therapy in AML/MDS patients

Jacqueline Garcia, MD, of Dana-Farber Cancer Institute presented at #ASH24 data suggesting oral maintenance therapy with venetoclax and decitabine/cedazuridine after HCT is safe, feasible, and may reduce relapse rates in high-risk AML/MDS patients.

  • January 9, 2025

  • 1 min